John Ternus Signals Apple’s Future with Product-First AI Strategy 
Want to cut your energy bills? Here’s how five experts are doing it 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
MALVERN, Pa., March 17, 2016 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, will release its fourth quarter and full year 2015 financial results after the market close on Wednesday, March 23, 2016.
Management will conduct a conference call at 4:30 p.m. ET that day to discuss the Company’s financial results and provide a general business update. The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors Relations” section of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. A replay of the webcast will be archived on the Company’s website for 30 days following the call.
To participate on the live call, please dial (877) 481-7177 (domestic) or (262) 558-6167 (international), and reference conference ID 50890341 prior to the start of the call.
About Aclaris
Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated drugs to address significant unmet needs in dermatology. Aclaris Therapeutics, Inc. is based in Malvern, Pennsylvania and more information can be found by visiting the company’s website at www.aclaristx.com.
Contact: Aclaris Contact Frank Ruffo Chief Financial Officer 484-324-7933 [email protected] Investor Contact Patricia L. Bank Westwicke Partners Managing Director 415-513-1284 [email protected] Media Contact Mike Beyer Sam Brown, Inc. 312-961-2502 [email protected]
